These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28952409)

  • 21. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
    Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
    Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
    Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
    Librizzi M; Caradonna F; Cruciata I; Dębski J; Sansook S; Dadlez M; Spencer J; Luparello C
    Chem Res Toxicol; 2017 Dec; 30(12):2187-2196. PubMed ID: 29129070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer.
    Li M; Viswanadhapalli S; Santhamma B; Pratap UP; Luo Y; Liu J; Altwegg KA; Tang W; Liu Z; Li X; Ebrahimi B; Yan H; Zou Y; Konda S; Sareddy GR; Xu Z; Chen Y; Rao MK; Brenner AJ; Kaklamani VG; Tekmal RR; Ahmed G; Raj GV; Nickisch KJ; Nair HB; Vadlamudi RK
    Commun Biol; 2021 Oct; 4(1):1235. PubMed ID: 34716410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 27. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
    Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
    Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
    Librizzi M; Spencer J; Luparello C
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    Fremd C; Jaeger D; Schneeweiss A
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
    Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
    Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and Anti-Triple Negative Metastatic Breast Tumor Cell Properties of Psammaplins.
    Zhou YD; Li J; Du L; Mahdi F; Le TP; Chen WL; Swanson SM; Watabe K; Nagle DG
    Mar Drugs; 2018 Nov; 16(11):. PubMed ID: 30423844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab for the treatment of triple-negative breast cancer.
    Heimes AS; Schmidt M
    Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors in clinical development.
    Rosato RR; Grant S
    Expert Opin Investig Drugs; 2004 Jan; 13(1):21-38. PubMed ID: 14680450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging approaches for histone deacetylase inhibitor drug discovery.
    Zwergel C; Valente S; Jacob C; Mai A
    Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
    Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
    Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.